sur SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Reports Strong Growth and Record Margins for FY 2024
SCHOTT Pharma AG & Co. KGaA achieved robust financial results for the fiscal year 2024. Revenues grew by 12% at constant currencies, reaching EUR 957 million, with EBITDA rising to EUR 258 million. The EBITDA margin improved to 26.9%, attributed to high demand for the company's high-value solutions (HVS), which constituted 55% of annual revenue.
The Drug Delivery Systems (DDS) segment was a key driver, achieving EUR 439 million in revenue, up 28% year-on-year. The Drug Containment Solutions (DCS) segment also saw positive growth at constant currencies. SCHOTT Pharma's innovations, such as the improved SCHOTT TOPPAC® Nest 160 for syringes, supported growth by enhancing sustainability and efficiency.
Looking ahead, SCHOTT Pharma anticipates continued strong revenues and earnings growth, driven by product innovation and capacity expansion.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SCHOTT Pharma AG & Co. KGaA